CA2326114A1 - Periadventitial delivery device - Google Patents
Periadventitial delivery device Download PDFInfo
- Publication number
- CA2326114A1 CA2326114A1 CA002326114A CA2326114A CA2326114A1 CA 2326114 A1 CA2326114 A1 CA 2326114A1 CA 002326114 A CA002326114 A CA 002326114A CA 2326114 A CA2326114 A CA 2326114A CA 2326114 A1 CA2326114 A1 CA 2326114A1
- Authority
- CA
- Canada
- Prior art keywords
- product according
- matrix material
- agent
- nucleic acid
- body part
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 34
- 239000011159 matrix material Substances 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 239000000565 sealant Substances 0.000 claims abstract description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 11
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 10
- 102000008186 Collagen Human genes 0.000 claims description 9
- 108010035532 Collagen Proteins 0.000 claims description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 9
- 229920001436 collagen Polymers 0.000 claims description 9
- 238000001356 surgical procedure Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 6
- 208000037804 stenosis Diseases 0.000 claims description 6
- 230000036262 stenosis Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000002847 Surgical Wound Diseases 0.000 claims description 4
- 239000003292 glue Substances 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 4
- 238000002399 angioplasty Methods 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 210000001147 pulmonary artery Anatomy 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 201000006306 Cor pulmonale Diseases 0.000 claims 1
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 238000013171 endarterectomy Methods 0.000 claims 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims 1
- 229960001123 epoprostenol Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims 1
- 230000003874 surgical anastomosis Effects 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 description 19
- 239000007943 implant Substances 0.000 description 19
- 210000001367 artery Anatomy 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000013598 vector Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000003038 endothelium Anatomy 0.000 description 4
- 210000003137 popliteal artery Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003106 tissue adhesive Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000003872 anastomosis Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 229920000260 silastic Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 101150021183 65 gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 230000003881 arterial anastomosis Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- ZXTYDZYHMVIHLP-UHFFFAOYSA-N cyano 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC#N ZXTYDZYHMVIHLP-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- -1 mentioned above Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000003894 surgical glue Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/047—Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
- C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Encapsulation Of And Coatings For Semiconductor Or Solid State Devices (AREA)
- Sampling And Sample Adjustment (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9809082.2A GB9809082D0 (en) | 1998-04-28 | 1998-04-28 | Delivery device |
| GB9809082.2 | 1998-04-28 | ||
| GB9810429.2 | 1998-05-14 | ||
| GBGB9810429.2A GB9810429D0 (en) | 1998-04-28 | 1998-05-14 | Delivery service |
| PCT/GB1999/001310 WO1999055315A1 (en) | 1998-04-28 | 1999-04-28 | Periadventitial delivery device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2326114A1 true CA2326114A1 (en) | 1999-11-04 |
Family
ID=26313555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002326114A Abandoned CA2326114A1 (en) | 1998-04-28 | 1999-04-28 | Periadventitial delivery device |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1073427B1 (enExample) |
| JP (1) | JP2002512951A (enExample) |
| KR (1) | KR100588714B1 (enExample) |
| CN (1) | CN1195502C (enExample) |
| AT (1) | ATE282408T1 (enExample) |
| AU (1) | AU738514B2 (enExample) |
| CA (1) | CA2326114A1 (enExample) |
| DE (1) | DE69921980T2 (enExample) |
| DK (1) | DK1073427T3 (enExample) |
| ES (1) | ES2232133T3 (enExample) |
| GB (2) | GB9809082D0 (enExample) |
| HU (1) | HUP0101631A3 (enExample) |
| NO (1) | NO20005398L (enExample) |
| PL (1) | PL194265B1 (enExample) |
| PT (1) | PT1073427E (enExample) |
| WO (1) | WO1999055315A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596699B2 (en) | 1998-09-22 | 2003-07-22 | Biosurface Engineering Technologies, Inc. | Nucleic acid coating compositions and methods |
| SE0000285D0 (sv) * | 1999-12-07 | 2000-01-31 | Mika Lahtinen | Medical implant |
| WO2007022287A2 (en) | 2005-08-15 | 2007-02-22 | Vegenics Limited | Modified vegf and pdgf with improved angiogenic properties |
| KR101241059B1 (ko) * | 2011-03-04 | 2013-03-11 | 연세대학교 산학협력단 | 마이크로 니들을 이용한 혈관외벽 장착 약물 전달장치 및 약물 전달방법 |
| US12102324B2 (en) * | 2018-10-02 | 2024-10-01 | Tmd Lab Co., Ltd. | Vascular anastomotic member comprising shape-memory polymer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3797485A (en) * | 1971-03-26 | 1974-03-19 | Alza Corp | Novel drug delivery device for administering drug into blood circulation in blood vessel |
| US5540928A (en) | 1991-02-27 | 1996-07-30 | President And Fellows Of Harvard College | Extraluminal regulation of the growth and repair of tubular structures in vivo |
| US5399352A (en) | 1993-04-14 | 1995-03-21 | Emory University | Device for local drug delivery and methods for using the same |
| GB2298577B (en) | 1995-03-09 | 1999-02-17 | Univ Bristol | Arteriovenous bypass grafting |
| US5766584A (en) * | 1995-06-02 | 1998-06-16 | Massachusetts Institute Of Technology | Inhibition of vascular smooth muscle cell proliferation with implanted matrix containing vascular endothelial cells |
| PT941116E (pt) | 1996-11-01 | 2005-05-31 | Ark Therapeutics Ltd | Utilizacao de vegf para o fabrico de um medicamento para o tratamento ou prevencao de hiperplasia da intima e dispositivo de entrega |
-
1998
- 1998-04-28 GB GBGB9809082.2A patent/GB9809082D0/en not_active Ceased
- 1998-05-14 GB GBGB9810429.2A patent/GB9810429D0/en not_active Ceased
-
1999
- 1999-04-28 CN CNB998055336A patent/CN1195502C/zh not_active Expired - Fee Related
- 1999-04-28 JP JP2000545514A patent/JP2002512951A/ja not_active Withdrawn
- 1999-04-28 EP EP99919391A patent/EP1073427B1/en not_active Expired - Lifetime
- 1999-04-28 AU AU37193/99A patent/AU738514B2/en not_active Ceased
- 1999-04-28 WO PCT/GB1999/001310 patent/WO1999055315A1/en not_active Ceased
- 1999-04-28 DE DE69921980T patent/DE69921980T2/de not_active Expired - Fee Related
- 1999-04-28 DK DK99919391T patent/DK1073427T3/da active
- 1999-04-28 PT PT99919391T patent/PT1073427E/pt unknown
- 1999-04-28 PL PL99343725A patent/PL194265B1/pl unknown
- 1999-04-28 KR KR1020007011341A patent/KR100588714B1/ko not_active Expired - Fee Related
- 1999-04-28 CA CA002326114A patent/CA2326114A1/en not_active Abandoned
- 1999-04-28 HU HU0101631A patent/HUP0101631A3/hu unknown
- 1999-04-28 ES ES99919391T patent/ES2232133T3/es not_active Expired - Lifetime
- 1999-04-28 AT AT99919391T patent/ATE282408T1/de not_active IP Right Cessation
-
2000
- 2000-10-26 NO NO20005398A patent/NO20005398L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2232133T3 (es) | 2005-05-16 |
| WO1999055315A1 (en) | 1999-11-04 |
| EP1073427B1 (en) | 2004-11-17 |
| DE69921980T2 (de) | 2005-04-07 |
| KR100588714B1 (ko) | 2006-06-13 |
| ATE282408T1 (de) | 2004-12-15 |
| DK1073427T3 (da) | 2005-01-24 |
| NO20005398D0 (no) | 2000-10-26 |
| HUP0101631A3 (en) | 2003-09-29 |
| GB9810429D0 (en) | 1998-07-15 |
| CN1298298A (zh) | 2001-06-06 |
| DE69921980D1 (de) | 2004-12-23 |
| HUP0101631A2 (hu) | 2002-03-28 |
| CN1195502C (zh) | 2005-04-06 |
| AU738514B2 (en) | 2001-09-20 |
| PT1073427E (pt) | 2005-01-31 |
| AU3719399A (en) | 1999-11-16 |
| JP2002512951A (ja) | 2002-05-08 |
| GB9809082D0 (en) | 1998-06-24 |
| PL194265B1 (pl) | 2007-05-31 |
| EP1073427A1 (en) | 2001-02-07 |
| KR20010034775A (ko) | 2001-04-25 |
| PL343725A1 (en) | 2001-09-10 |
| NO20005398L (no) | 2000-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU729420B2 (en) | Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia | |
| US8455453B2 (en) | Use of VEGF-D gene to prevent restenosis | |
| US5833651A (en) | Therapeutic intraluminal stents | |
| US20070287682A1 (en) | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor | |
| ES2229788T3 (es) | Uso del gen o proteina vegf-c o vegf-d para prevenir la restenosis. | |
| JP2004537344A (ja) | 医療装置 | |
| WO1993000052A1 (en) | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor | |
| AU738514B2 (en) | Periadventitial delivery device | |
| US20030039694A1 (en) | Periadventitial delivery device | |
| JP2002512951A5 (enExample) | ||
| MXPA00010167A (es) | Dispositivo para suministro periadventicio | |
| JP2006503605A (ja) | 医療装置 | |
| EP1568375A1 (en) | Use of VEGF-C or VEGF-D gene or protein to prevent restenosis | |
| HK1108845B (en) | Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device | |
| MXPA99004088A (en) | Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia | |
| AU2002303052A1 (en) | Medical device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |